This page provides an overview of therapeutic concepts and ideas for neurodegenerative diseases generated through NeuroWiki's knowledge synthesis. These ideas represent novel combinations of existing mechanistic evidence with therapeutic hypotheses. [1]
| Category | Target | Rationale | Status | [2]
|----------|--------|-----------|--------|
| Amyloid Reduction | Aβ production/clearance | Core pathology | In clinical trials |
| Tau Modulation | Phosphorylation/aggregation | Spreading mechanism | In clinical trials |
| Alpha-synuclein | Aggregation inhibitors | PD core pathology | Phase 2 |
| Neuroprotection | Multiple pathways | Broad benefit | Preclinical |
| Category | Target | Rationale | Status |
|---|---|---|---|
| Cognitive Enhancement | Glutamatergic signaling | Memory improvement | Approved |
| Motor Modulation | Dopaminergic system | Motor function | Approved |
| Behavioral Control | Serotonergic system | Neuropsychiatric | Approved |
Combining multiple mechanisms:
Genetic and biomarker-driven approaches:
Restoring lost function:
| Drug | Original Use | Neurodegeneration Potential |
|---|---|---|
| Metformin | Diabetes | Neuroprotection |
| Saracatinib | Cancer | Src inhibition |
| Losartan | Hypertension | AT1R blockade |
| Ibuprofen | Pain | Anti-inflammatory |
Cummings J, et al. Alzheimer's disease drug development. Alzheimer's Dement. 2024. 2024. ↩︎
Kalia LV, et al. [Parkinson's disease: pathogenesis. Lancet Neurol. 2023](https://doi.org/10.1016/S1474-4422(23). 2023. ↩︎